Difference between revisions of "Bupropion-duloxetine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = duloxetine  
 
| to = duloxetine  
 
| stop =  
 
| stop =  
* Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
+
{{stopBupropion}}
* When a dosage of 150 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
* No wash-out period is needed.
+
{{Inc25p3d2}}
* Start duloxetine the next day in normal dosage of 60 mg/day.
+
* Start duloxetine in dosage of 60 mg/day.
 
| info =  
 
| info =  
 +
* No wash-out period is needed.
 
* Bupropion and its metabolites have long elimination times, so plasma concentrations will reduce gradually.
 
* Bupropion and its metabolites have long elimination times, so plasma concentrations will reduce gradually.
{{review}}
+
 
 
}}
 
}}

Revision as of 11:35, 14 October 2015

Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine

Switch medication from bupropion to duloxetine.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Day 1: Stop bupropion.
  • bupropion can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start duloxetine
  • Day 2: Start with normal dosage and increase with about 25% (up to 50%) every 3 days to target dose.
  • Start duloxetine in dosage of 60 mg/day.
Infobord.png More information
  • No wash-out period is needed.
  • Bupropion and its metabolites have long elimination times, so plasma concentrations will reduce gradually.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Multidisciplinair document Afbouwen Overige Antidepressiva 2023
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.